2020
Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020
Weinberger DM, Chen J, Cohen T, Crawford FW, Mostashari F, Olson D, Pitzer VE, Reich NG, Russi M, Simonsen L, Watkins A, Viboud C. Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020. JAMA Internal Medicine 2020, 180: 1336-1344. PMID: 32609310, PMCID: PMC7330834, DOI: 10.1001/jamainternmed.2020.3391.Peer-Reviewed Original ResearchConceptsCOVID-19Excess deathsOfficial COVID-19 deathsCoronavirus disease 2019Entire US populationPublic health impactCOVID-19 diagnostic testsCOVID-19 burdenCOVID-19 deathsCause deathReported deathsMortality burdenObservational studyDisease 2019Influenza activityMAIN OUTCOMEDeath AssociatedWeekly deathsTotal deathsUS deathsMore deathsDeath recordsUS populationHealth StatisticsTest availability
2012
Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation
Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLOS Medicine 2012, 9: e1001347. PMID: 23185139, PMCID: PMC3502465, DOI: 10.1371/journal.pmed.1001347.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBCost-effectiveness ratioInitial diagnosisXpert MTB/RIF testMTB/RIF testXpert MTB/RIFIntroduction of XpertTB natural historyTB-HIV coinfectionMultidrug-resistant tuberculosisHigh HIV prevalenceMTB/RIFHealth system costsImplementation of XpertHealth impactsPopulation health impactCost-effectiveness resultsLong-term transmission dynamicsWorld Health OrganizationAntiretroviral therapyTB casesTB deathsTB morbidityHIV prevalenceRIF test